Amyris Inc (AMRSQ)

[north40000]

Some innovative and useful aspects of genetic engineering seems to be working well for Amyris: fermentation of sugar cane husks, that once were mostly ignored as a raw material source.

The hybridized strain of pseudomonas bacteria in Diamond v. Chakrabarty, 447 U.S. 303(1980), was where/when I first became actively involved in litigation in genetic-engineering during the mid-1970s. GE did apply a strain to help clean up the Valdez oil spill. I doubt GE was able to monetize all its efforts to any great extent.
Perhaps GE will do better under new CEO Culp and the remains of its health sector. Our recent investments in GE have slightly negative value so far

Better monetization occurred by DNA and Roche with the cell culture of various recombinant molecules against the Bose patent, later canceled to be replaced by the DNA patent that was licensed and accrued healthy royalty sums for ~ two decades. I consulted with counsel representing DNA for two days in Scottsdale in proceedings leading to Roche/DNA obtaining the grant of the Cabllly patent. We never invested in either company(conflicts) except to the extent they carry weight in LABU.

We held/hold profitable, LT investments in IMCL(acquired by LLY); MEDX(acquired by BMY); AMLN(acquired by BMY/AZN); OCAT (acquired by Astellas) and GILD, CORT, VCEL, CPRX, ARYC, INSM, JNJ, SGEN, and AMRN, among others.

I’ll leave the collection of the loose change that you mention to you. We invested in Amyris for substantial value creation; we bought further shares today.

Both of us recognize that ST and LT losses do exist; we have our share of those too.